BioCentury
ARTICLE | Clinical News

Hylenex: Phase I data

July 19, 2010 7:00 AM UTC

In a 6-way crossover, double-blind Phase I trial in 14 healthy volunteers, the addition of rHuPH20 to Apidra insulin glulisine, Humalog insulin lispro or NovoLog insulin aspart increased insulin exposure during the first hour after injection to 191%, 229% and 246%, respectively, compared with each insulin alone (p<0.0001 for all). After 2 hours, insulin exposure in the presence of rHuPH20 decreased by 43%, 54% and 57%, respectively, vs. each insulin alone. Additionally, 50% of total insulin exposure times significantly decreased from 125, 123 and 131 minutes for Apidra, Humalog and NovoLog alone, respectively, to 79, 71 and 73 minutes when co-administered with rHuPH20 (p<0.0001 for all). Data were presented at the American Diabetes Association meeting in Orlando. ...